WO2015066377A1 - Method for scalable skeletal muscle lineage specification and cultivation - Google Patents
Method for scalable skeletal muscle lineage specification and cultivation Download PDFInfo
- Publication number
- WO2015066377A1 WO2015066377A1 PCT/US2014/063250 US2014063250W WO2015066377A1 WO 2015066377 A1 WO2015066377 A1 WO 2015066377A1 US 2014063250 W US2014063250 W US 2014063250W WO 2015066377 A1 WO2015066377 A1 WO 2015066377A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell line
- differentiation
- myogenic
- self
- cell
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 68
- 210000002027 skeletal muscle Anatomy 0.000 title description 21
- 241001465754 Metazoa Species 0.000 claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 claims abstract description 20
- 210000004027 cell Anatomy 0.000 claims description 141
- 230000004069 differentiation Effects 0.000 claims description 53
- 230000001114 myogenic effect Effects 0.000 claims description 48
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 claims description 42
- 229960003722 doxycycline Drugs 0.000 claims description 34
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims description 34
- 108091023040 Transcription factor Proteins 0.000 claims description 28
- 102000040945 Transcription factor Human genes 0.000 claims description 27
- 210000000130 stem cell Anatomy 0.000 claims description 21
- 230000001939 inductive effect Effects 0.000 claims description 18
- 230000001973 epigenetic effect Effects 0.000 claims description 17
- 101000958865 Homo sapiens Myogenic factor 5 Proteins 0.000 claims description 16
- 102100032970 Myogenin Human genes 0.000 claims description 16
- 239000001963 growth medium Substances 0.000 claims description 16
- 239000003112 inhibitor Substances 0.000 claims description 16
- 102100038380 Myogenic factor 5 Human genes 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 12
- 244000144972 livestock Species 0.000 claims description 11
- 210000001087 myotubule Anatomy 0.000 claims description 10
- 230000004156 Wnt signaling pathway Effects 0.000 claims description 9
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 9
- -1 BIO Chemical compound 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 8
- 102100028914 Catenin beta-1 Human genes 0.000 claims description 7
- 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 230000002068 genetic effect Effects 0.000 claims description 7
- 210000003205 muscle Anatomy 0.000 claims description 7
- 230000004070 myogenic differentiation Effects 0.000 claims description 7
- 108010077544 Chromatin Proteins 0.000 claims description 6
- 101000613490 Homo sapiens Paired box protein Pax-3 Proteins 0.000 claims description 6
- 102100040891 Paired box protein Pax-3 Human genes 0.000 claims description 6
- 210000003483 chromatin Anatomy 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- 230000033228 biological regulation Effects 0.000 claims description 5
- 238000011161 development Methods 0.000 claims description 5
- 235000005911 diet Nutrition 0.000 claims description 5
- 230000000378 dietary effect Effects 0.000 claims description 5
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 5
- 244000144977 poultry Species 0.000 claims description 5
- 241000283690 Bos taurus Species 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 4
- 238000011160 research Methods 0.000 claims description 4
- 108010033040 Histones Proteins 0.000 claims description 3
- 102000006947 Histones Human genes 0.000 claims description 3
- 101000958866 Homo sapiens Myogenic factor 6 Proteins 0.000 claims description 3
- 101000601661 Homo sapiens Paired box protein Pax-7 Proteins 0.000 claims description 3
- 102100038379 Myogenic factor 6 Human genes 0.000 claims description 3
- 102100037503 Paired box protein Pax-7 Human genes 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000010362 genome editing Methods 0.000 claims description 3
- 210000001082 somatic cell Anatomy 0.000 claims description 3
- HPTXLHAHLXOAKV-INIZCTEOSA-N (2S)-2-(1,3-dioxo-2-isoindolyl)-3-(1H-indol-3-yl)propanoic acid Chemical compound O=C1C2=CC=CC=C2C(=O)N1[C@H](C(=O)O)CC1=CNC2=CC=CC=C12 HPTXLHAHLXOAKV-INIZCTEOSA-N 0.000 claims description 2
- DXYYSGDWQCSKKO-UHFFFAOYSA-N 2-methylbenzothiazole Chemical compound C1=CC=C2SC(C)=NC2=C1 DXYYSGDWQCSKKO-UHFFFAOYSA-N 0.000 claims description 2
- MDYDGUOQFUQOGE-UHFFFAOYSA-N 2-methylpropanethioic acid S-[7-oxo-7-[(4-phenyl-2-thiazolyl)amino]heptyl] ester Chemical compound S1C(NC(=O)CCCCCCSC(=O)C(C)C)=NC(C=2C=CC=CC=2)=C1 MDYDGUOQFUQOGE-UHFFFAOYSA-N 0.000 claims description 2
- JCSGFHVFHSKIJH-UHFFFAOYSA-N 3-(2,4-dichlorophenyl)-4-(1-methyl-3-indolyl)pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(C)C=C1C(C(NC1=O)=O)=C1C1=CC=C(Cl)C=C1Cl JCSGFHVFHSKIJH-UHFFFAOYSA-N 0.000 claims description 2
- MAUCONCHVWBMHK-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)-oxomethyl]phenoxy]ethyl]-2-benzofurancarboxamide Chemical compound O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MAUCONCHVWBMHK-UHFFFAOYSA-N 0.000 claims description 2
- ZKJAZFUFPPSFCO-UHFFFAOYSA-N 3-[2-(4-fluorophenyl)ethylamino]-1-methyl-4-(2-methyl-1H-indol-3-yl)pyrrole-2,5-dione Chemical compound CC=1NC2=CC=CC=C2C=1C=1C(=O)N(C)C(=O)C=1NCCC1=CC=C(F)C=C1 ZKJAZFUFPPSFCO-UHFFFAOYSA-N 0.000 claims description 2
- VPVLEBIVXZSOMQ-UHFFFAOYSA-N 3-[[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol Chemical compound NC1=CC=CC(C=2NC3=NC=NC(OC=4C=C(O)C=CC=4)=C3C=2)=C1 VPVLEBIVXZSOMQ-UHFFFAOYSA-N 0.000 claims description 2
- JHSXDAWGLCZYSM-UHFFFAOYSA-N 4-(4-chloro-2-methylphenoxy)-N-hydroxybutanamide Chemical compound CC1=CC(Cl)=CC=C1OCCCC(=O)NO JHSXDAWGLCZYSM-UHFFFAOYSA-N 0.000 claims description 2
- RZWRYPGAUIOOMK-UHFFFAOYSA-N 5-nitroso-8-quinolinol Chemical compound C1=CN=C2C(O)=CC=C(N=O)C2=C1 RZWRYPGAUIOOMK-UHFFFAOYSA-N 0.000 claims description 2
- JTDYUFSDZATMKU-UHFFFAOYSA-N 6-(1,3-dioxo-2-benzo[de]isoquinolinyl)-N-hydroxyhexanamide Chemical compound C1=CC(C(N(CCCCCC(=O)NO)C2=O)=O)=C3C2=CC=CC3=C1 JTDYUFSDZATMKU-UHFFFAOYSA-N 0.000 claims description 2
- VUWMSJQZENJPHO-UHFFFAOYSA-N 7-oxo-7-(n-phenylanilino)heptanoic acid Chemical compound C=1C=CC=CC=1N(C(=O)CCCCCC(=O)O)C1=CC=CC=C1 VUWMSJQZENJPHO-UHFFFAOYSA-N 0.000 claims description 2
- 241001550224 Apha Species 0.000 claims description 2
- RFLHBLWLFUFFDZ-UHFFFAOYSA-N BML-210 Chemical compound NC1=CC=CC=C1NC(=O)CCCCCCC(=O)NC1=CC=CC=C1 RFLHBLWLFUFFDZ-UHFFFAOYSA-N 0.000 claims description 2
- MDZCSIDIPDZWKL-UHFFFAOYSA-N CHIR-98014 Chemical compound C1=C([N+]([O-])=O)C(N)=NC(NCCNC=2N=C(C(=CN=2)N2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1 MDZCSIDIPDZWKL-UHFFFAOYSA-N 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 230000007067 DNA methylation Effects 0.000 claims description 2
- 102000016680 Dioxygenases Human genes 0.000 claims description 2
- 108010028143 Dioxygenases Proteins 0.000 claims description 2
- 102000008157 Histone Demethylases Human genes 0.000 claims description 2
- 108010074870 Histone Demethylases Proteins 0.000 claims description 2
- 102000011787 Histone Methyltransferases Human genes 0.000 claims description 2
- 108010036115 Histone Methyltransferases Proteins 0.000 claims description 2
- 102000003893 Histone acetyltransferases Human genes 0.000 claims description 2
- 108090000246 Histone acetyltransferases Proteins 0.000 claims description 2
- 102000003964 Histone deacetylase Human genes 0.000 claims description 2
- 108090000353 Histone deacetylase Proteins 0.000 claims description 2
- 102000016397 Methyltransferase Human genes 0.000 claims description 2
- 108060004795 Methyltransferase Proteins 0.000 claims description 2
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 claims description 2
- YALNUENQHAQXEA-UHFFFAOYSA-N N-[4-[(hydroxyamino)-oxomethyl]phenyl]carbamic acid [6-(diethylaminomethyl)-2-naphthalenyl]methyl ester Chemical compound C1=CC2=CC(CN(CC)CC)=CC=C2C=C1COC(=O)NC1=CC=C(C(=O)NO)C=C1 YALNUENQHAQXEA-UHFFFAOYSA-N 0.000 claims description 2
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 claims description 2
- KPNNXHVGOKRBEF-UHFFFAOYSA-N N-hydroxy-7-(2-naphthalenylthio)heptanamide Chemical compound C1=CC=CC2=CC(SCCCCCCC(=O)NO)=CC=C21 KPNNXHVGOKRBEF-UHFFFAOYSA-N 0.000 claims description 2
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 claims description 2
- 229950008805 abexinostat Drugs 0.000 claims description 2
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 claims description 2
- 229960003094 belinostat Drugs 0.000 claims description 2
- HQSSEGBEYORUBY-WPWMEQJKSA-N chembl597845 Chemical compound C=1C=CC(\N=C\C=2C3=CC=CC=C3C=CC=2O)=CC=1NC(=O)C(C)C1=CC=CC=C1 HQSSEGBEYORUBY-WPWMEQJKSA-N 0.000 claims description 2
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims description 2
- YAEMHJKFIIIULI-UHFFFAOYSA-N n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea Chemical compound C1=CC(OC)=CC=C1CNC(=O)NC1=NC=C([N+]([O-])=O)S1 YAEMHJKFIIIULI-UHFFFAOYSA-N 0.000 claims description 2
- OYKBQNOPCSXWBL-SNAWJCMRSA-N n-hydroxy-3-[(e)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide Chemical compound ONC(=O)\C=C\C1=CC=CC(C(=O)NO)=C1 OYKBQNOPCSXWBL-SNAWJCMRSA-N 0.000 claims description 2
- 229960005184 panobinostat Drugs 0.000 claims description 2
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims description 2
- 238000007634 remodeling Methods 0.000 claims description 2
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims description 2
- VAZAPHZUAVEOMC-UHFFFAOYSA-N tacedinaline Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 claims description 2
- PMJIHLSCWIDGMD-UHFFFAOYSA-N tideglusib Chemical compound O=C1SN(C=2C3=CC=CC=C3C=CC=2)C(=O)N1CC1=CC=CC=C1 PMJIHLSCWIDGMD-UHFFFAOYSA-N 0.000 claims description 2
- 229950005284 tideglusib Drugs 0.000 claims description 2
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims description 2
- GOVYBPLHWIEHEJ-UHFFFAOYSA-N tubastatin A Chemical compound C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=C(C(=O)NO)C=C1 GOVYBPLHWIEHEJ-UHFFFAOYSA-N 0.000 claims description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 2
- 229960000237 vorinostat Drugs 0.000 claims description 2
- DVNYTAVYBRSTGK-UHFFFAOYSA-N 5-aminoimidazole-4-carboxamide Chemical compound NC(=O)C=1N=CNC=1N DVNYTAVYBRSTGK-UHFFFAOYSA-N 0.000 claims 1
- 101000589002 Homo sapiens Myogenin Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000000646 extraembryonic cell Anatomy 0.000 claims 1
- 235000013372 meat Nutrition 0.000 abstract description 23
- 230000002708 enhancing effect Effects 0.000 abstract description 5
- 235000012041 food component Nutrition 0.000 abstract description 4
- 238000004113 cell culture Methods 0.000 abstract description 3
- 230000011712 cell development Effects 0.000 description 36
- 230000014509 gene expression Effects 0.000 description 34
- 230000006698 induction Effects 0.000 description 22
- 241000894007 species Species 0.000 description 20
- 239000002609 medium Substances 0.000 description 19
- 238000001262 western blot Methods 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 16
- 108010056785 Myogenin Proteins 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 238000005516 engineering process Methods 0.000 description 14
- 230000004913 activation Effects 0.000 description 13
- 230000005283 ground state Effects 0.000 description 13
- 210000000107 myocyte Anatomy 0.000 description 12
- 238000001514 detection method Methods 0.000 description 11
- 108700019146 Transgenes Proteins 0.000 description 10
- 230000030833 cell death Effects 0.000 description 10
- 210000002242 embryoid body Anatomy 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 101001023043 Homo sapiens Myoblast determination protein 1 Proteins 0.000 description 9
- 108010085895 Laminin Proteins 0.000 description 9
- 102000007547 Laminin Human genes 0.000 description 9
- 241001529936 Murinae Species 0.000 description 9
- 102100035077 Myoblast determination protein 1 Human genes 0.000 description 9
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 108010082117 matrigel Proteins 0.000 description 9
- 230000007704 transition Effects 0.000 description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
- 239000004472 Lysine Substances 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
- 239000011575 calcium Substances 0.000 description 8
- 229910052791 calcium Inorganic materials 0.000 description 8
- 239000000306 component Substances 0.000 description 8
- 238000002372 labelling Methods 0.000 description 8
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 7
- 108090000672 Annexin A5 Proteins 0.000 description 7
- 102000004121 Annexin A5 Human genes 0.000 description 7
- 102100036912 Desmin Human genes 0.000 description 7
- 108010044052 Desmin Proteins 0.000 description 7
- 230000001464 adherent effect Effects 0.000 description 7
- 210000005045 desmin Anatomy 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 210000001778 pluripotent stem cell Anatomy 0.000 description 7
- 150000003384 small molecules Chemical class 0.000 description 7
- 241000272517 Anseriformes Species 0.000 description 6
- 102100029855 Caspase-3 Human genes 0.000 description 6
- 101000793880 Homo sapiens Caspase-3 Proteins 0.000 description 6
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 6
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 6
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 6
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
- 230000008602 contraction Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 210000003716 mesoderm Anatomy 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 5
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 229960002756 azacitidine Drugs 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000004114 suspension culture Methods 0.000 description 5
- 230000001052 transient effect Effects 0.000 description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 4
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 4
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 102000013814 Wnt Human genes 0.000 description 4
- 108050003627 Wnt Proteins 0.000 description 4
- 101150063416 add gene Proteins 0.000 description 4
- 229930189065 blasticidin Natural products 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 229960005309 estradiol Drugs 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000012239 gene modification Methods 0.000 description 4
- 230000005017 genetic modification Effects 0.000 description 4
- 235000013617 genetically modified food Nutrition 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 4
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 230000022379 skeletal muscle tissue development Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 230000009495 transient activation Effects 0.000 description 4
- 102000015735 Beta-catenin Human genes 0.000 description 3
- 108060000903 Beta-catenin Proteins 0.000 description 3
- 102100038595 Estrogen receptor Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 3
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 3
- 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 description 3
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000025164 anoikis Effects 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960001948 caffeine Drugs 0.000 description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 108020001756 ligand binding domains Proteins 0.000 description 3
- 235000013622 meat product Nutrition 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000003365 myofibril Anatomy 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000269350 Anura Species 0.000 description 2
- 241000030939 Bubalus bubalis Species 0.000 description 2
- 241000282832 Camelidae Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 241000238366 Cephalopoda Species 0.000 description 2
- 241000282994 Cervidae Species 0.000 description 2
- 241000283153 Cetacea Species 0.000 description 2
- 241000272201 Columbiformes Species 0.000 description 2
- 241000270722 Crocodylidae Species 0.000 description 2
- 241000238424 Crustacea Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 102100021291 Methyl-CpG-binding domain protein 3 Human genes 0.000 description 2
- 101710111894 Methyl-CpG-binding domain protein 3 Proteins 0.000 description 2
- 241000237852 Mollusca Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 206010043276 Teratoma Diseases 0.000 description 2
- 241000270666 Testudines Species 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000009360 aquaculture Methods 0.000 description 2
- 244000144974 aquaculture Species 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 238000003352 cell adhesion assay Methods 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000002135 phase contrast microscopy Methods 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- PTNZGHXUZDHMIQ-CVHRZJFOSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-CVHRZJFOSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 101100328086 Caenorhabditis elegans cla-1 gene Proteins 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine group Chemical group N[C@H](CCCCN)C(=O)O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 1
- 101000582994 Homo sapiens Myelin regulatory factor Proteins 0.000 description 1
- 101150088952 IGF1 gene Proteins 0.000 description 1
- 101150013833 MYOD1 gene Proteins 0.000 description 1
- 102100030372 Myelin regulatory factor Human genes 0.000 description 1
- 101710099061 Myogenic factor 5 Proteins 0.000 description 1
- 239000012580 N-2 Supplement Substances 0.000 description 1
- 240000007019 Oxalis corniculata Species 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- 241001112090 Pseudovirus Species 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 102100024837 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 3 Human genes 0.000 description 1
- 101710188227 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 3 Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 230000010632 Transcription Factor Activity Effects 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- FKAWLXNLHHIHLA-YCBIHMBMSA-N [(2r,3r,5r,7r,8s,9s)-2-[(1s,3s,4s,5r,6r,7e,9e,11e,13z)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraenyl]-9-[(e)-3-[2-[(2s)-4-[[(2s,3s,4s)-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanoyl]amino]butan-2-yl]-1,3-oxazol-4 Chemical compound O1C([C@@H](C)CCNC(=O)[C@@H](O)[C@@H](O)[C@H](COC)N(C)C)=NC(\C=C\C[C@H]2[C@H]([C@H](O)C[C@]3(O2)C([C@@H](OP(O)(O)=O)[C@@H]([C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)\C=C(/C)\C(\C)=C\C=C\C(\C)=C/C#N)OC)O3)(C)C)C)=C1 FKAWLXNLHHIHLA-YCBIHMBMSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000010868 animal carcass Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000046645 human LIF Human genes 0.000 description 1
- 229950011479 hyclate Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000002235 sarcomere Anatomy 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000024642 stem cell division Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
- C12N2501/392—Sexual steroids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/602—Sox-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/604—Klf-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Definitions
- the present disclosure relates to methods for enhancing cultured meat production, such as livestock-autonomous meat production.
- the conceptual promises of "cultured meat” include increased production efficiency, reduced environmental impacts, expanded culinary application utility, enhanced nutritional value, pest-free production and improved food safety relative to conventionally produced meats. Technologies, to date however, have not advanced sufficiently to support scalable, economically sustainable production.
- the current laboratory-scale cultivation of prototype tissues has utilized primary animal components such as animal tissues and serum, thereby largely negating the advantages of animal- autonomous meat production.
- current methods fail to resolve the animal dependence from cultured meat production sufficiently to realize the conceptual promises of "cultured meat” and provide a commercially advantageous product. Therefore, there is a need to provide new and improved methods for scalable meat cultivation from a self- renewing source in vitro for dietary nutrition and other applications.
- the example embodiments provide a scalable platform for skeletal muscle cultivation that utilizes cell lines with the potential to differentiate as skeletal muscle.
- the cell lines are from livestock such as domestic cattle, pigs, sheep, goats, camels, water buffalo, rabbits and the like.
- the cells lines are from poultry such as domestic chicken, turkeys, ducks, geese, pigeons and the like.
- the cell lines are from common game species such as wild deer, gallinaceous fowl, waterfowl, hare and the like.
- the cell lines are from aquatic species or semi-aquatic species harvested commercially from wild fisheries or aquaculture operations, or for sport, including certain fish, crustaceans, mollusks, cephalopods, cetaceans, crocodilians, turtles, frogs and the like.
- the cell lines are from exotic, conserved or extinct animal species.
- the cell lines are from any metazoan species demonstrating the capacity for skeletal muscle tissue specification.
- the cell lines are for research or for therapeutic purposes, such as humans, primates, rodents including rats and mice, and companion animals such as dogs, cats, horses, and the like.
- the cell lines from any organisms are self-renewing stem cell lines.
- the selected cell line is modified by a 'genetic switch' to induce rapid and efficient conversion of cells to skeletal muscle for cultured meat production.
- the above or other aspects may be accomplished by a method comprising modifying a selected self-renewing cell line by a myogenic transcription factor to produce a myogenic-transcription-factor- modified cell line, and inducing such modified cell line by exogenous regulation to direct alternate self-renewal or differentiation processes.
- the self-renewing cell line is selected from a group consisting of embryonic stem cells, induced pluripotent stem cells, somatic cell lines, or extra- embryotic cell lines with myogenic potential.
- the cell line is derived from species intended for dietary consumption.
- myogenic transcription factors include, alone or in combination, MYOD1, MYOG, MYF5, MYF6, PAX3, PAX7, paralogs, orthologs, genetic variants thereof, or transcriptional activation agonists of the respective promoter recognition DNA sequences of the myogenic transcription factors as further described herein.
- an inducible MyoD transcription factor may be used as the differentiation lineage specifier.
- the porcine induced pluripotent cell line 02K may be employed as the self-renewing cell line.
- the method comprises modifying a 02K stem cell line with an inducible MyoD transcription factor to produce a myogenic-transcription-factor-modified 02KM cell line, and inducing such 02KM cell line by exogenous regulation to direct self-renewal or differentiation processes.
- the aforementioned modifying step can further comprise modifying the cell line with a chromosomally integrated vector constitutively expressing an inducible fusion of the MYOD1 transcription factor and an ESR1 ligand binding domain from a constitutively active promoter region.
- the inducible activity of the translated fusion transcript e.g., MyoDER
- the ESR1 agonist e.g., 17- ⁇ Estradiol (E2)
- the inducing step can further comprise the self-renewal sub-step and the differentiation sub-step regulated by a double-switch mechanism.
- the self- renewal sub-step the modified cell line undifferentiated ground-state is preserved, such as in the presence of doxycycline (DOX), whereby the cell line is maintained in a stem cell self-renewal state by the induced expression of the pluripotency transgenes POU5F1 and KLF4.
- DOX doxycycline
- the modified cell line is treated, such as with E2 in the absence of DOX, whereas the cell line is efficiently specified to skeletal myocytes, i.e., the myogenic lineage, by the inducible MyoD transcription factor, resulting in characteristic elongated cells with spindle-like morphology.
- the derivative myocytes can fuse into multinucleated myotubes, precursors to skeletal muscle fibers.
- the differentiation sub-step can further comprise adding certain reagents in the culture medium for activating the canonical WNT signaling pathway to prevent cell death and facilitate myogenic differentiation, and adding epigenetic modulators to the culture medium to alter the chromatin structure for enhanced myogenic gene expression.
- Certain aspects of the disclosure employ genetically enhanced cells for unlimited renewal capacity and efficient conversation to skeletal muscle, the predominant tissue lineage constituting non-offal meat products, in serum-free culture medium.
- tissue engineering approach When coupled with a scalable tissue engineering approach, such methods can revolutionize the way meat is produced and marketed for consumers by enabling cultivation of animal tissue in unlimited quantities for animal-autonomous cultured meat production. Additional applications contemplated include in vivo xeno-transplantation use and in vitro models for drug screening, developmental physiology, and developmental biology.
- Figure 1 shows a MyoDER DNA sequence.
- Figure 2 is a schematic illustration of a method comprising a double-switch regulation mechanism for expansion of the undifferentiated cell line, or skeletal muscle lineage specification.
- Figure 3 is a schematic illustration showing a double-switch mechanism applied to the myogenic modified 02KM cell line regulated by DOX or E2.
- Figure 4A is a schematic illustration of the selectable MyoDER transgene expression cassette. Arrows and boxes respectively indicate promoter and gene sequences.
- Figure 4B shows Western blot image detection of MyoDER transgene expression in blastidicin-selected 02K by an anti-MYODl antibody.
- Transgene expression cassette modified 02K is designated as 02KM.
- TUBA alpha- tubulin
- Figure 5 is an image showing 02KM cells exhibiting stable, compact-colony morphology in self-renewal conditions as the parental 02K cell line.
- Figure 6 is a panel of images showing 02KM cultured on Poly-D-
- Figure 7 shows Western blot analysis of MYOD1 (MyoD), MYF5
- Myf5 Myf5
- MYOG myogenin
- Figure 8 shows images of immuno fluorescent detection of myocyte cell surface marker NCAM (Alexa568) and nuclei (DAPI) in 5AC-exposed 02KM cultures prior to, and following, a 2-day 10 ⁇ E2 induction time-course.
- NCAM myocyte cell surface marker NCAM
- DAPI nuclei
- Figure 9 shows a panel of phase-contrast images of i. ground state undifferentiated 02K colonies cultured on Poly-D Lysine + Gelatin + Laminin under 5%
- Figure 11 shows a bar graph of flow cytometric analysis of
- Annexin V labeled cells Undifferentiated 02K colonies were cultured under 20% 0 2 in differentiation medium the presence of 0, 1, 3 or 6 ⁇ CHIR99021 for one day prior to analysis.
- Figure 12 shows Western Blot analysis of relative CTNNB1 ( ⁇ - catenin) levels and phosphorylation (p-CTNNBl) at GSK3P substrates serine 33, 37 and threonine 41 in cultures differentiated from the ground-state (as shown in FIG. 9 ) in the presence of CHIR99021 at the concentrations indicated. Cultures were exposed to 50 nM Calyculin A and 30 ⁇ MG-132 for 3 hours prior to harvest to stabilize detectable levels of p-CTNNBl for comparative analysis.
- Figure 13 A shows a graph illustrating the densitomentric ratios of p-CTNNBl/CTNNBl bands as shown in Figure 12.
- Figure 13B shows a graph illustrating the densitometric ratios of
- Figure 14 shows an image illustrating the differentiation marker time-course Western blot analysis. Expression levels of pluripotency markers, POU5F1 and KLF4, and the pre -myogenic paraxial mesoderm marker PAX3 in 02K cultures differentiated from the ground state in the presence of CHIR99021.
- Figure 15 shows images of terminal differentiation of 02KM myocytes differentiated in the absence (left panel) or presence (right panel) of 5-Aza- Cytidine (5 AC). Note the myocyte derivatives with flattened morphology in the left panel (-5 AC) in contrast to the elongated, multinucleated myotubes in the left panel (+5 AC).
- Figure 16 shows Annexin V labeling of apoptotic cells prior to, and following 24h transition of cultures, as in Figure 9, panels i-ii.
- Figure 17A shows Western blot detection of full-length CPP32
- Figure 17B shows Western blot detection of full-length CPP32 and the cleaved fragment in colonies following 42h transition to the differentiation milieu in the presence of CHIR99021 levels indicated.
- Figure 18 shows outgrowth morphology of embryoid bodies formed in a differentiation milieu containing 6 ⁇ CHIR99021 for two days and following transfer to a Poly-D Lysine + Laminin + MATRIGEL coated substrate for one
- Figure 19A shows Western Blot of lysates from unmodified piPSC cultured in the absence of 3i, DOX, hLIF and E2 in differentiation milieu containing
- Figure 19B shows Western Blot of lysates from MyoDER- modified piPSC cultured in the presence of DOX, LIF and 3i. MYODER-modified piPSC were cultured 3 days in self-renewal or expansion milieu.
- Figure 20A is a schematic of the 02KM expansion and induction regimens, followed by the terminal differentiation regimen.
- Figure 20B shows myotube morphology and conformation.
- Post- induction (d2), piPSC developed as elongated, anisotropic, refractive myotubes when exposed to 5AC during the expansion and induction regimens.
- Figure 20C shows uniform expression of myosin heavy chain by d6.
- Figure 20D shows myotube multinucleation.
- Left panel enlarged image of d4 terminal differentiation cultures. Bracketed arrows indicate multiple nuclei within a single myotube.
- Figure 20E Western blots show increasing expression of desmin
- Figure 20F shows cell-cycle withdrawal concomitant with terminal differentiation.
- Figure 20G shows Transmission Electron Microscopy of d6 myotubes. Sarcomeric structural units were aligned in single ⁇ left panels) and staggered, parallel rows ⁇ right panel).
- Figure 21 A shows asynchronous, single-cell transient cycles ⁇ left, middle and right panels) were observed in spontaneously contracting d6 myotube subpopulations.
- Figure 2 IB shows FOV activation and synchronization of calcium transient cycles by 1.0 Hz field stimulation in d6 myotubes.
- Figure 21C shows FOV calcium transient activation of d6 myotubes by 10 mM caffeine.
- Figure 2 ID Figures 2 ID: single-cell analysis of calcium transient activation in a d7 myotubes by 100 nM acetylcholine. DETAILED DESCRIPTION
- a or “an” entity refers to one or more of that entity; for example, “a polynucleotide,” is understood to represent one or more polynucleotides.
- the terms “a” (or “an”), “one or more,” and “at least one” can be used interchangeably herein.
- meat is any metazoan tissue or cell-derived comestible product intended for use as a comestible food or nutritional component by humans, companion animals, domesticated or captive animals whose carcasses are intended for comestible use, service animals, conserved animal species, animals used for experimental purposes, or cell cultures.
- the cell source is a stem cell source, for example, a self-renewable stem cell line.
- Certain aspect of the methods employ a myogenic, inducible transgene -modified self-renewable cell line derived from an intended species.
- the intended species can be any edible species including livestock and poultry species.
- the intended species are livestock species such as domestic cattle, pigs, sheep, goats, camels, water buffalo, rabbits and the like.
- the intended species are poultry species such as domestic chicken, turkeys, ducks, geese, pigeons and the like.
- the intended species are common game species such as wild deer, gallinaceous fowl, waterfowl, hare and the like.
- the intended species are aquatic species or semi-aquatic species harvested commercially from wild fisheries or aquaculture operations, or for sport, including certain fish, crustaceans, mollusks, cephalopods, cetaceans, crocodilians, turtles, frogs and the like.
- the intended species are exotic, conserved or extinct animal species.
- the intended species are any metazoan species demonstrating the capacity for skeletal muscle tissue specification.
- the intended species are for research or for therapeutic purposes, such as humans, primates, rodents including rats and mice, and companion animals such as dogs, cats, horses, and the like.
- the cell line is regulated by a double-switch mechanism to either maintain the cell line in self-renewal process or direct myogenic differentiation.
- a parent/host cell line of aspects disclosed herein has the properties of being immortal (self-renewing) and having the potential to differentiate, reprogram, specify or otherwise convert to skeletal muscle lineage, such as following regimens comprising one or more components that direct myogenic conversion.
- Three classes of stem cell may be employed as cell sources for scalable cultivation: (1) lineage-restricted primary adult progenitor stem cell isolations, (2) lineage-restricted immortalized cell lines, and (3) pluripotent stem cells lines. It has been determined that each of these approaches has advantages and disadvantages in serving as a cell source for cultured meat production.
- Lineage-Restricted Primary Adult Progenitor Stem Cell Isolations include adult progenitor cells committed to lineages constituting meat products such as skeletal muscle. Skeletal muscle progenitor cells include, but are not limited, to satellite cells, myoblasts and myocytes. Their advantages include: i) primary adult progenitor cells are restricted to specific lineages and require little or no in vitro specification to desired lineages; and ii) primary adult progenitor cells do not require genetic modification for lineage specification. Their disadvantages include: i) they must either be harvested from a freshly slaughtered animal carcass or procured from an invasive biopsy.
- Either method conveys dependence on livestock and compromises the benefit of livestock- autonomous production to the extent that livestock are used in the process;
- primary cell isolation is a highly inefficient process.
- the desired cells comprise a fraction of the source tissue. A subtraction of the desired cells survive the isolation process. Desired cell lineages must be isolated from mixed populations of surviving cells, requiring additional purification and expansion steps;
- primary adult progenitor cells are subject to the 'Hayflick Limit', wherein cells can divide only limited number of times before they lose their capacity to proliferate. Moreover, primary adult progenitor cells lose their ability to terminally differentiate in a manner concordant with extended passage.
- Lineage-Restricted Immortalized Cell Lines are lineage-committed primary cells that are genetically altered to self-renew indefinitely while retaining their capacity to terminally differentiate or lineage-restricted.
- Their advantages include: i) "perpetually self-renewing" (i.e. not subject to the 'Hayflick Limit') and can expand indefinitely for scalable and livestock-autonomous cultivation; ii) restricted to specific lineages and require little or no further in vitro specification.
- Their disadvantages include: i) immortalized, lineage-restricted cell lines from certain species with the capacity to differentiate along lineages applicable to cultured meat production (e.g.
- skeletal muscle may require development; ii) cultures of lineage-committed cell lines are anchorage dependent, limiting scalability. In suspension culture, lineage-committed cell lines may be susceptible to cell death by anoikis; and iii) cellular transformation(s) enabling 'immortalization' necessitates genetic modification. The necessary genetic modifications that immortalize applicable primary cell populations without interfering with their capacity to terminally differentiate are not well characterized.
- Pluripotent Stem Cells Lines include embryonic stem cells or induced pluripotent stem cells (iPSC) that maintain the capacity to self-renew in the undifferentiated state, or alternately differentiate to any tissue lineage.
- iPSC induced pluripotent stem cells
- Their advantages include: i) in general, pluripotent stem cell lines proliferate at a higher rate than primary or immortalized lineage-restricted cell lines, reducing the time required for biomass expansion in production processes; ii) pluripotent stem cells may be cultivated as embryoid bodies in suspension culture, thereby enhancing culture scalability per unit of culture volume.
- embryoid bodies may be cultured as 'bio-ink' compatible with micromold and bioprinting tissue assembly methods; and iii) like immortalized lineage- restricted cell lines, pluripotent stem cells are not subject to the 'Hayflick Limit' and can expand indefinitely for scalable, livestock-autonomous cultivation.
- Their disadvantages include: i) authentic embryonic stem cell lines derived from certain species may require development; ii) methods for reprogramming and self-renewal of iPSC may be transgene- dependent. Hence, iPSC pluripotency may require genetic modification for induction and self-renewal of the undifferentiated state.
- Efficient iPSC differentiation requires mechanisms for silencing the transgenes used for reprogramming and maintenance of the undifferentiated state mutually exclusive to the differentiated state to avoid conflicting transcription network activation disadvantageous to desired lineage specification; and iii) relative to lineage-restricted primary adult progenitor stem cells and immortalized cell lines, pluripotent stem cells, in general, require additional lineage specification steps to develop and enrich the desired lineage specification.
- induced trophoblast cell lines (representing non-pluripotent, non-somatic immortalized cells of extra-embryonic type), whose myogenic potential was established previously by the teratoma assay, may be suitable for myogenic conversion as well.
- somatic cell lines partially reprogrammed to pluripotency may possess myogenic potential but fail to form teratomas representing three embryonic germ layers.
- STAP cell lines (stimulus-triggered acquisition of pluripotency) may be myo-potent and self-renewing.
- 02K cell line is an induced pluripotent stem cell line established from the inner cell mass of a pre-implantation porcine embryo.
- the 02K cell line has been studied and it was discovered that the self-renewal state of 02K can be maintained by transcriptional activation of POU5F1 and KLF4 transgenes by doxycycline (i.e. DOX) using a 'Tet-On' induction system.
- DOX doxycycline
- MYOD1 transcription factor is a dominant regulator of skeletal muscle lineage commitment.
- the MyoDER construct has been described previously, consisting of a genetic fusion of the murine MYOD1 gene and the sequence encoding the ligand binding domain of the human estrogen receptor a, shown in Figure 1 (SEQ ID NO: 1).
- the MyoDER consists of a genetic fusion between the murine MYODI gene at the Nar I restriction endonuclease digest site with the ligand binding domain coding sequence of the ESR1 (i.e. human estrogen receptor a) nucleotides 844-1781.
- ESR1 i.e. human estrogen receptor a
- MyoDER fusion construct The myogenic specification activity of the MyoDER fusion construct is post-translationally induced by addition of the estrogen receptor a ligand, 17P-Estradiol (i.e., E2). In the absence of the 17P-estradiol, MyoDER remains in an inactive state.
- the MyoDER construct is herein referred to as "inducible MyoD.”
- one aspect is cell-stock-expansion, i.e., expansion of the cell line in self-renewal conditions necessary for the maintenance of cell stocks for continued scalable cultivation.
- Another aspect is the lineage-specification/differentiation, i.e., inducing myogenic lineage differentiation for further tissue cultivation process.
- certain aspects may be summarized as comprising two main steps: i) modifying a selected self-renewing cell line with a myogenic transcription factor to produce an myogenic-transcription-factor-modified cell line, and ii) inducing such modified cell line by exogenous regulation to maintain in self-renewal process or advance to differentiation process.
- modifying" a cell line with an myogenic transcription factor refers to inserting a nucleic acid vector or construct operably encoding a myogenic transcription factor (such as by transfection, transduction, transformation, and the like) into the cell line, wherein the modified cell line expresses the myogenic transcription factor.
- the inserted myogenic transcription factor is inducibly- expressed to produce an inducible-myogenic transcription factor cell modified cell line.
- inducibly refers to any genetically engineered approaches that may be used to exogenously regulate the activities of a gene product such as a myogenic transcription factor.
- Inducible approaches include, but are not limited to, regulation of myogenic transcription factor activity by ligand inducible transcription factor technology (e.g., tet-on, tet-off, RheoSwitch), site-directed recombination technology (e.g., Cre-LoxP, flp-FRT), transposon technology (e.g. Sleeping Beauty, PiggyBac), ligand binding receptor fusion technology (e.g., estrogen, progesterone, androgen, thyroid hormone, glucocorticoid hormone, tamoxifen ligand agonists), and transient transfection of extrachromosomal expression vectors bearing a myogenic transcription factor gene.
- ligand inducible transcription factor technology e.g., tet-on, tet-off, RheoSwitch
- site-directed recombination technology e.g., Cre-LoxP, flp-FRT
- transposon technology
- the nucleic acid construct or vector is chromosomally integrated into the modified cell line.
- self- renewing cell lines include those selected from a group consisting of embryonic stem cells, induced pluripotent stem cells, and immortal lineage -restricted cell lines. In certain aspects, such self-renewing cell lines are derived from species intended for dietary consumption or for research or for therapeutic purposes.
- myogenic transcription factors include, used alone or in combination, MYOD1 , MYOG, MYF5, MYF6, PAX3, PAX7, paralogs, orthologs, genetic variants thereof, or transcriptional activation agonists of the respective promoter recognition DNA sequences of the myogenic transcription factors disclosed herein.
- Figure 3 includes exemplary schematic illustrations of the double-switch mechanism of the myogenic modified 02KM cell line regulated by DOX or E2.
- the expression of the pluripotency transgenes POU5F1 and KLF4 is induced in the presence of DOX in the self-renewal medium (SRM), while such expression is repressed when DOX is absent.
- SRM self-renewal medium
- myogenic differentiation is activated by the inducible MyoD transgene in the presence of E2 in the myogenic induction medium (MIM), while such directed differentiation is inactive when E2 is absent.
- MIM myogenic induction medium
- Certain aspects provide differentiation/specification methods comprising additional reagents other than E2 in the MIM to prevent cell death and to modulate the epigenetic state of chromatin.
- additional reagents other than E2 in the MIM for example, a Glyogen Synthase Kinase-3P (GSK3P) inhibitor can be added to the SRM and MIM to activate the canonical WNT signaling pathway, in turn, enhance myogenic differentiation and reduce cell death at the time of DOX withdrawal.
- GSK3P Glyogen Synthase Kinase-3P
- the epigenetic modular alters the chromatin activation by myogenic transcription factors and/or enhances expression of myogenic transcription factors, such as MYF5.
- GSK3P inhibition includes targeting with small-molecules.
- GSK3P may be inhibited in the host/parental cell line by mutating the GSK3P alleles either by sequence-specific insertion or deletion technology (i.e. Zinc-Finger Nuclease, TALEN, CRISPR). Mutating the endogenous promotor region can be used to repress expression of GSK3p. Alternately, the GSK3P open reading frame may be deleted or mutated using the same methods to abolish GSK3P activity.
- sequence-specific insertion or deletion technology i.e. Zinc-Finger Nuclease, TALEN, CRISPR.
- Mutating the endogenous promotor region can be used to repress expression of GSK3p.
- the GSK3P open reading frame may be deleted or mutated using the same methods to abolish GSK3P activity.
- beta-catenin may be mutated at the codons coding for residues phosphorylated by GSK3P, thereby preventing phosphorylation of CTNNB1 by GSK3P, resulting in a constitutively active, stable CTNNBl .
- Such "gene-editing" methods would reduce the cost of GSK3P inhibition by small-molecule targeting and potentially improve the safety profile of the meat product, as additional chemicals would not be required to inhibit GSK3P during the process.
- a third approach to Wnt-signaling inhibition includes the use of anti-sense nucleic acid inhibitors to GSK3P or other factors antagonistic to the WNT pathway. These may include RNA interference methods using sequence-targeting shRNA or miRNA.
- GSK3P inhibitors to promote cell survival, for example at the time of DOX withdrawal.
- a GSK3P inhibitor is CHIR99021.
- Additional representative GSK3P inhibitors may include, without limitation: lithium chloride, BIO, SB216763, CHIR-98014, TWS119, Tideglusib, IM-12, 1-Azakenpullone, AR-A014418, and SB415286. Without being bound by theory, it is believed that concomitant with DOX, both self-renewal of undifferentiated cells is maintained by a WNT signaling pathway involving the inhibition of GSK3p.
- the GSK3P inhibitor enhanced expression of the myogenic transcription factor MYF5 in differentiating 02K.
- a GSK3P inhibitor such as CHIR99021 , enhanced the terminal differentiation of the myogenic murine C2C 12 cell line into multi-nucleated myotubes, as shown in Table 1.
- Table 1 lists the influences of extracellular matrix effectors (i.e. Gelatin, Poly-D-).
- Lysine, Laminin, MATRIGEL Lysine, Laminin, MATRIGEL
- soluble factors E2, CHIR99021
- DOX withdraw (2) supporting differentiation toward the pre-myogenic state, (3) enhancing myogenic specification, and (4) enhancing terminal differentiation, a GSK3P inhibitor when retained in the culture medium during differentiation (in the absence of DOX), is deemed compatible with the inducible myogenic transcription factor directed lineage specification and subsequent terminal differentiation conditions by derivative myocytes.
- CHIR99021 was retained in the 02KM cultures following DOX withdrawal during subsequent E2-induced lineage-specification and terminal differentiation processes.
- MYF5 expression was enhanced and cells exhibited a refractive myofibril morphology, whereas myocytes derived in the absence of 5AC expressed reduced MYF5 and exhibited an flattened morphology atypical to mature myofibrils. This distinction may explained by the enhanced expression of the myogenic transcription factor MYF5 observed only in the 5AC-exposed 02KM prior to and following 48 hours of DOX withdrawal
- non- phosphorylated myogenin isoform known to be the active transactivator
- the morphological distinction among these cultures may be explained by MYF5 expression enhanced by 5AC exposure.
- epigenetic modulation entails alteration of chromatin structure influencing transcription factor binding and targeted transcriptional activation by altering the DNA methylation patterns and post-translational modification of nucleosome- associated histones.
- epigenetic modulation may entail small-molecule agonists or antagonists targeting epigenetic pathways or expressed proteins comprising epigenetic machinery.
- a small-molecule epigenetic modulator is 5-Aza-Cytidine (5AC).
- small molecule epigenetic modulators include 5-Aza-2'-deoxycytidine, RG108, Scriptaid, sodium butyrate, trichostatin A, Suberoylanilide Hydroxamic Acid, MS-275, CI-994, BML-210, M344, MGCD0103, PXD101, LBH-589, Tubastatin A, NSC3825, NCH-51, NSC-3852, HNHA, BML-281, CBHA, Salermide, Pimelic Diphenylamide, ITF-2357, PCI-24781, APHA Compound 8, Droxinostat, and SB-939.
- proteins involved in epigenetic modulation include histone deacetylase paralogs, histone acetyltransferase paralogs, tet-methycytosine dioxygenase paralogs, histone demethylase paralogs, histone methyltransferase paralogs, and DNA methyltransferase paralogs, histones, and subunits of chromatin remodeling complexes including Mi-2/NuRD (and its components such as methyl-CpG-binding domain protein 3 (MBD2) ) and SWI/SNF (and its components such as BAF60 and BAF60C).
- Mi-2/NuRD and its components such as methyl-CpG-binding domain protein 3 (MBD2)
- SWI/SNF and its components such as BAF60 and BAF60C
- respective activities of protein epigenetic modulators may be influenced by representative modalities such as targeting by small-molecule factors, over-expression of a respective exogenous transcript, anti-sense RNA-targeted respective transcript degradation, RNAi, and targeted mutation at the genetic locus.
- 02KM cell line was derived from the parental 02K cell line by lentiviral insertion of a blastidicin-selectable transgene cassette containing the MyoDER open reading frame sequence (ORF).
- ORF MyoDER open reading frame sequence
- 02K cells/cell line and piPSC cells are used interchangeably.
- the lentiviral vector, illustrated in Figure 4A was prepared by cloning the MyoDER ORF (Addgene #13494) downstream of the CMV promoter of the pLentiCMVBlast destination vector (Addgene # 17451) between the attRl and attR2 recombination sites from an pENTR/D-TOPO entry vector (Life Technologies #K2435-20) clone containing the PCR-amp lifted MyoDER ORF.
- 293FT cells were co-transfected with the prepared pLentiCMVBlast[MyoDER] plasmid, the pMD2.G envelope plasmid (Addgene #12259) and the psPAX2 packaging plasmid (Addgene #12260) using the PolyJet transfection reagent (Signagen # SL100688).
- 02K was transduced with pseudovirus concentrated from the 293FT supernatant.
- Transduced 02K were cultured in phenol-red free culture medium and selected four days with 10 ⁇ g/mL blasticidin followed by two additional days with 15 ⁇ / ⁇ , blasticidin. Selected cells were designated as 02KM. Expression of MyoDER in the 02KM stock was verified by Western blot, Figure 4B
- 02 KM stem cell stock expansion in presence of DOX 02KM stem cell renewal milieu was conducted as for the parental 02K line, with the following exception: phenol- red free formulations of DMEM/F-12 and neurobasal medium were substituted for the phenol-red containing formulations to avert pleotropic agonistic effects on MyoDER (i.e. activation).
- the 02KM cell stock self-renewal medium consisted of the following components: phenol-red- free neurobasal medium (Life Technologies #12348- 017), phenol-red free DMEM-F12 (Life Technologies #11039-021), IX non-essential amino acids (Sigma-Aldrich #M7145), 0.5X Glutamax (Life Technologies #35050061), 0.000007% ⁇ -Mercaptoethanol, 0.5X N2 Supplement (Life Technologies #17502048), 0.5X B27 Supplement Minus Vitamin A (Life Technologies #12587010), 0.1 mg/mL Bovine Serum Albumin, 2 ⁇ g/mL doxacycline hyclate (i.e.
- a culture medium formulation including CHIR99021 when retained in the SRM basal medium in the absence of hLIF, DOX, PD032591 and PD173074, supported both cell survival during differentiation as determined by (1) phase-contrast microscopy, as shown in Figure 9, panels iii. - viii., (2) cell adhesion assay, as shown in Figure 10, (3) CPP32 cleavage inhibition as shown in Figure 17B, and (4) Annexin V labeling, as shown in Figure 11.
- CHIR99021 exposure during primordial differentiation stabilizes and modulates the phosphorylation status of the GSK3P substrate, CTNNB1, as shown in Figure 12, 13 A and 13B, the phospho-regulated downstream effector of the canonical WNT signaling pathway known to direct mesodermal differentiation during embryonic lineage specification, myogenic enrichment of mesodermal progenitors, and terminal differentiation of skeletal myocytes.
- CHIR99021 supplemented basal medium supported pre-myogenic paraxial mesoderm lineage specification of differentiating 02K, as shown in Figure 14 and when included in low- mitogen differentiation cultures (2% horse serum/DMEM) of the myogenic murine C2C12 cell line, enhanced terminal differentiation into skeletal myotubes, listed in Table. 1.
- 02KM myogenic induction 02KM cells were seeded onto culture dishes coated with poly-D lysine, murine laminin and MATRIGEL at a density of 4.1 x 10 3 cells/cm 2 and cultured under 5% 0 2 in self-renewal medium for 3d. To facilitate differentiation, cultures were transferred to a 20% 0 2 basal differentiation milieu, designated by withdrawal of PD032591, PD 173074, DOX, hLIF and ⁇ -mercaptoethanol. To conditionally induce the expressed MyoDER protein, 10 ⁇ E2 was added to the medium.
- E2-directed myogenic lineage specification following 2d induction culture was confirmed by (1) adoption of spindle-like morphology characteristic of skeletal myocytes in treated cultures, as shown in Figure 6, (2) expression of endogenous the MYOG skeletal muscle transcription factor, as shown in Figure 7 and (3) uniform expression of the skeletal myocyte cell surface marker, NCAM, as shown in Figure 8.
- the gene expression program in the 02KM-derived myocytes was not sufficient to enable terminal differentiation as per the established conditions.
- 5 AC a small-molecule epigenetic modulator, was determined previously to enable skeletal muscle transcription in cell lines non-permissive to myogenesis.
- 5AC exposure was further determined to enhance terminal differentiation by the C2C12 cell line.
- 250 nM 5AC the highest dose tolerated by undifferentiated 02KM, was included during in the proliferative 02KM expansion and induction regimens, as shown in Figure 20A.
- TDM terminal differentiation medium
- N-2 and B-27 supplements were used exclusively as serum replacements.
- Cultures were differentiated for up to 6d following under 20% 0 2 following induction regimens ( Figure 20A). Cultures exposed to 5AC during expansion and induction regimens formed refractive, anisotropic myotubes during the terminal differentiation regimen, shown in Figure 20B.
- Figure 20C shows uniform expression of myosin heavy chain by d6, and Figure 20E shows increasing expression of desmin (DES) and myogenin (MYOG) over the 8d course.
- Myotube polyploidy was observed during terminal differentiation, as shown in Figure 20D, left panel.
- the relative distribution of myonuclei in d8 myotubes according to ploidy is shown in Figure 20D, right panel.
- Contractile potential of terminally differentiating skeletal muscle myotubes was validated by (1) structural development of well-organized sarcomeres, as shown in Figure 20G; (2) asynchronous spontaneous contraction, as shown in Figure 21 A; (3) contractile stimulation and synchronization by field stimulation, as shown in Figure 2 IB; (4) caffeine-stimulated contraction, as shown in Figure 21C; and (5) acetylcho line-stimulated contraction, as shown in Figure 2 ID.
- FIG. 9 shows phase-contrast images of ground-state piPSC colonies cultured under 5% 0 2 in the self-renewal milieu (i.) and following 48h under 20% 0 2 in the absence of DOX, LIF and 3i, (ii.).
- Figure 16 shows Annexin V labeling of apoptotic cells prior to, and following 24h transition of cultures.
- Figure 17A shows Western blot detection of full- length CPP32 ( ⁇ 32 kD procaspase 3a) and the large cleaved fragment ( ⁇ 17kD cleaved- caspase 3a) in ground-state colonies prior to (Oh) and following (12-48h) differentiation milieu transition (12-48h).
- Figure 9 shows phase contrast images of adherent cultures (iii, iv, vi, and vi) and non-adherent embryoid body cultures (vii and viii) following 48h culture in differentiation milieu supplemented with CHIR99021 as indicated.
- Figure 11 shows Annexin V labeling of apoptotic cells following 24h transition of cultures to differentiation milieu supplemented with CHIR99021 as indicated.
- Figure 17B shows Western blot detection of full-length CPP32 and the cleaved fragment in colonies following 42h transition to the differentiation milieu in the presence of CHIR99021 levels indicated.
- TUBA is detected an internal protein loading control.
- CHIR99021 stabilizes CTNNBl and supports differentiation from the ground state.
- Figure 12 shows Western blot detection of CTNNBl and p-CTNNBl (total and phospho-S33,37,T41 ⁇ -catenin, respectively) following 24h differentiation milieu transition in the presence of CHIR99021, as indicated.
- TUBA detected as an internal protein loading control.
- Figure 13A indicates ratios of p-CTNNBl /CTNNBl bands.
- Figure 13B indicates ratios of CTNNB1/TUBA bands.
- Figure 18 shows outgrowth morphology of embryoid bodies formed in a differentiation milieu containing 6 ⁇ CHIR99021 for two days and following transfer to a Poly-D Lysine + Laminin + MATRIGEL coated substrate for one (d3, left panel) or three (d5, right panel) additional days.
- Figure 14 shows Western blot analysis of PAX3, POU5F1 and KLF4 expression in ground-state milieu (dO) and differentiation milieu cultures (dl - d5) according to one regimen aspect described elsewhere herein.
- TUBA detection is shown as an internal protein loading control.
- FIG. 4A shows a Blasticidin (BLAST)-selectable MyoDER expression cassette. Arrows and boxes indicate promoter and gene sequences, respectively.
- Figure 4B shows Western blot detection of MyoDER in the unmodified (02K) and MyoDER expression cassette-modified (02KM) piPSC line. MyoDER was detected with an antibody raised against a MyoD peptide.
- Figure 7 shows Western blot detection of MyoDER (-75 kD), MYF5 and MYOG following 2d piPSC induction. Endogenous MYOD1 (-45 kD, expected) was not detected.
- 02KM were seeded onto poly-D lysine + Martigel + murine laminin coated culture dishes and cultured with hLIF, 3i & DOX for three days in the presence (i.e. expansion, Figure 20A) or absence of 5 AC, followed by respective transition to a -/+ 5AC differentiation milieu supplemented with E2 (i.e. 17 ⁇ estradiol) and 3 ⁇ CHIR99021 for two days.
- Double Arrow Partially resolved MYOG isoforms.
- Figure 19A and 19B Determinants of MYF5 activation: Western blot analyses.
- FIG. 19A following three days of culture on poly-d-lysine + laminin + MATRIGEL, unmodified piPSC were cultured 2d in the absence of 3i, DOX, hLIF and E2 in differentiation milieu supplemented with 5 AC (as in Figure 7) and CHIR99021 as indicated.
- the 17 kD cleaved caspase isoform was not observed in the KOSR supplemented differentiation milieu, as in contrast to observations in the N-2 and B-27 supplemented differentiation milieu ( Figure 17A, Figure 19A).
- 5AC-enhanced activation of endogenous MYF5 expression was dependent upon simultaneous CHIR99021 exposure, as shown in FIG. 19A.
- FIG 19B shows MYF5 activation in the presence of DOX, LIF and 3i.
- MYODER-modified piPSC were cultured 3 days in self-renewal or expansion milieu.
- 5 AC exposure supported detectable MYF5 expression levels, as shown in Figure 19B, after 3 days of expansion culture.
- MYF5 was not detected following 3 days of renewal culture (-5AC), as shown in Figure 19B.
- TUBA is detected as an internal protein loading control.
- Figure 6 shows the morphology of selected piPSC cultures following lineage specification induction culture regimens ( Figure 20A) described elsewhere herein.
- Figure 8 shows immunocytoflourescent detection of nuclei (DAPI) and NCAM in piPSC-MyoDER cultures prior to (dO, left panel) and following (d2, right panel) 10 ⁇ E2 exposure, in the presence of 5 AC.
- Terminal Myogenesis of Lineage-Specified piPSC Prior to terminal differentiation, cultures were expanded for 3 days in the presence of 5 AC, induced for 2 days in the presence of E2 & 5 AC, and terminally differentiated in the absence of 5 AC & E2 as shown in Figure 20A.
- Figure 20B shows myotube morphology and conformation.
- Post-induction (d2), piPSC developed as elongated, anisotropic, refractive myotubes. Where 5AC was not included in the expansion and induction steps, cells exhibited a flattened, non-refractive morphology.
- Figure 20C and Figure 20E show terminal myogenesis protein expression.
- FIG. 20D shows myotube multinucleation.
- Left panel enlarged image of d4 terminal differentiation cultures. Bracketed arrows indicate multiple nuclei within a single myotube.
- Figure 20E shows Western blot analyses. MyoD (MYOD1), myogenin (MYOG) and desmin (DES) expression, dO -d8.
- TUBA is detected as an internal protein loading control.
- Figure 20G Transmission Electron Microscopy, d6 myotubes. Sarcomeric structural units were aligned in single ⁇ left panels) and staggered, parallel rows ⁇ right panel).
- Figure 21C shows FOV calcium transient activation of d6 myotubes by 10 mM caffeine.
- Figures 2 ID single-cell analysis of representative calcium transient activation in a d7 myotubes by 100 nM acetylcholine.
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL296889A IL296889A (en) | 2013-10-30 | 2014-10-30 | Method for scalable skeletal muscle lineage specification and cultivation |
JP2016552246A JP6728049B2 (en) | 2013-10-30 | 2014-10-30 | Expandable skeletal muscle lineage formation and culture methods |
AU2014342180A AU2014342180B2 (en) | 2013-10-30 | 2014-10-30 | Method for scalable skeletal muscle lineage specification and cultivation |
CN201480061537.7A CN105899079A (en) | 2013-10-30 | 2014-10-30 | Method for scalable skeletal muscle lineage specification and cultivation |
EP14858383.4A EP3071040B2 (en) | 2013-10-30 | 2014-10-30 | Method for scalable skeletal muscle lineage specification and cultivation |
ES14858383T ES2782380T5 (en) | 2013-10-30 | 2014-10-30 | Scalable Skeletal Muscle Lineage Culture and Specification Method |
US15/033,207 US20160251625A1 (en) | 2013-10-30 | 2014-10-30 | Method for scalable skeletal muscle lineage specification and cultivation |
CA2928726A CA2928726A1 (en) | 2013-10-30 | 2014-10-30 | Method for scalable skeletal muscle lineage specification and cultivation |
BR112016009803-0A BR112016009803B1 (en) | 2013-10-30 | 2014-10-30 | METHOD FOR SCALABLE SKELETAL MUSCLE LINE SPECIFICATION AND CULTIVATION |
US15/134,252 US10920196B2 (en) | 2013-10-30 | 2016-04-20 | Method for scalable skeletal muscle lineage specification and cultivation |
IL245292A IL245292B2 (en) | 2013-10-30 | 2016-04-24 | Method for scalable skeletal muscle lineage specification and cultivation |
AU2019202244A AU2019202244B2 (en) | 2013-10-30 | 2019-04-02 | Method for scalable skeletal muscle lineage specification and cultivation |
US17/175,324 US20210171912A1 (en) | 2013-10-30 | 2021-02-12 | Method for scalable skeletal muscle lineage specification and cultivation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361962068P | 2013-10-30 | 2013-10-30 | |
US61/962,068 | 2013-10-30 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/134,252 Continuation US10920196B2 (en) | 2013-10-30 | 2016-04-20 | Method for scalable skeletal muscle lineage specification and cultivation |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015066377A1 true WO2015066377A1 (en) | 2015-05-07 |
Family
ID=53005145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/063250 WO2015066377A1 (en) | 2013-10-30 | 2014-10-30 | Method for scalable skeletal muscle lineage specification and cultivation |
Country Status (10)
Country | Link |
---|---|
US (3) | US20160251625A1 (en) |
EP (1) | EP3071040B2 (en) |
JP (2) | JP6728049B2 (en) |
CN (2) | CN111154726A (en) |
AU (2) | AU2014342180B2 (en) |
BR (1) | BR112016009803B1 (en) |
CA (1) | CA2928726A1 (en) |
ES (1) | ES2782380T5 (en) |
IL (2) | IL296889A (en) |
WO (1) | WO2015066377A1 (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017124100A1 (en) * | 2016-01-14 | 2017-07-20 | Memphis Meats, Inc. | Methods for extending the replicative capacity of somatic cells during an ex vivo cultivation process |
WO2018011805A2 (en) | 2016-07-11 | 2018-01-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Systems and methods for growing cells in vitro |
WO2018208628A1 (en) | 2017-05-06 | 2018-11-15 | Memphis Meats, Inc. | Compositions and methods for increasing the culture density of a cellular biomass within a cultivation infrastructure |
WO2018227016A1 (en) * | 2017-06-07 | 2018-12-13 | Wild Type, Inc. | Ex vivo meat production |
US10920196B2 (en) | 2013-10-30 | 2021-02-16 | The Curators Of The University Of Missouri | Method for scalable skeletal muscle lineage specification and cultivation |
WO2021102375A1 (en) | 2019-11-20 | 2021-05-27 | Memphis Meats, Inc. | Apparatuses and systems for preparing a meat product |
WO2021111263A1 (en) * | 2019-12-02 | 2021-06-10 | Avant Meats Company Limited | Methods for improving cell growth with species-specific or genus-specific proteins and the applications thereof |
WO2021158831A1 (en) | 2020-02-04 | 2021-08-12 | Upside Foods, Inc. | Characteristics of meat products |
WO2021248141A1 (en) | 2020-06-05 | 2021-12-09 | Upside Foods, Inc. | Nutrient media for the production of slaughter-free meat |
WO2021250407A1 (en) * | 2020-06-10 | 2021-12-16 | HigherSteaks Limited | Systems and methods for cell conversion |
WO2022039998A1 (en) | 2020-08-18 | 2022-02-24 | Upside Foods, Inc. | Systems, devices, and methods for sterilizing bioreactors and culture media |
US11318167B2 (en) | 2015-12-11 | 2022-05-03 | The Johns Hopkins University | Isolation of fusion-competent myoblasts and therapeutic applications thereof related to muscular dystrophy |
WO2022140185A1 (en) * | 2020-12-22 | 2022-06-30 | Upside Foods, Inc. | Systems and methods for cultivating tissue on porous substrates |
WO2022140187A1 (en) * | 2020-12-21 | 2022-06-30 | Upside Foods, Inc. | Fluid conduit with radial expansion of fluid flow |
WO2022156939A1 (en) * | 2021-01-22 | 2022-07-28 | HigherSteaks Limited | Products for cell conversion |
WO2022216742A1 (en) | 2021-04-07 | 2022-10-13 | Upside Foods, Inc. | Generation of cell-based products for consumption that comprise proteins derived from exotic, endangered, and extinct species |
US11479792B2 (en) | 2017-07-13 | 2022-10-25 | Upside Foods, Inc. | Compositions and methods for increasing the efficiency of cell cultures used for food production |
WO2022232322A1 (en) | 2021-04-28 | 2022-11-03 | Upside Foods, Inc. | Generation of cell-based products for human consumption |
WO2022265632A1 (en) | 2021-06-16 | 2022-12-22 | Upside Foods, Inc. | Plant fat-based scaffolds for the growth of cell-based meats and methods of making such products |
WO2023281114A1 (en) | 2021-07-09 | 2023-01-12 | Suprême | Foodstuffs comprising cells differentiated from engineered oligopotent stem cells |
WO2023122688A1 (en) * | 2021-12-23 | 2023-06-29 | Upside Foods, Inc. | Scaling up myogenic tissue: late passage myogenicity |
GB202308833D0 (en) | 2022-06-14 | 2023-07-26 | Upside Foods Inc | Non-skeletal muscle-derived cells as a source of suspension capable myogenic cells for cultured foods |
EP4292440A1 (en) | 2022-06-14 | 2023-12-20 | Upside Foods, Inc. | Suspension based chicken product formulation |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2573327B (en) * | 2018-05-03 | 2021-05-12 | Mosa Meat Bv | Apparatus and process for production of tissue from cells |
SG11202113006VA (en) | 2019-05-28 | 2021-12-30 | Upside Foods Inc | Apparatuses and methods for preparing a comestible meat product |
CA3216903A1 (en) | 2021-05-06 | 2022-11-10 | Yeda Research And Development Co. Ltd. | Method for inducing hypertrophic muscle fibers for industrial meat production |
WO2023069991A1 (en) | 2021-10-19 | 2023-04-27 | Eat Scifi Inc. | Plant base/animal cell hybrid meat substitute |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0435617A1 (en) * | 1989-12-21 | 1991-07-03 | The University Of Georgia Research Foundation, Inc. | Bovine myogenic factor gene |
WO1993009236A1 (en) * | 1991-11-06 | 1993-05-13 | Baylor College Of Medicine | Myogenic vector systems |
US20110191871A1 (en) * | 2006-02-28 | 2011-08-04 | Trustees Of Boston University | Methods to identify factors associated with muscle growth and uses thereof |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5510254A (en) | 1986-04-18 | 1996-04-23 | Advanced Tissue Sciences, Inc. | Three dimensional cell and tissue culture system |
WO1999031222A1 (en) | 1997-12-18 | 1999-06-24 | Willem Frederik Van Eelen | Industrial scale production of meat from in vitro cell cultures |
US6264992B1 (en) | 1998-02-27 | 2001-07-24 | Purdue Research Foundation | Submucosa as a growth substrate for cells |
US6537782B1 (en) | 1998-06-01 | 2003-03-25 | Chugai Seiyaku Kabushiki Kaisha | Media for culturing animal cells and process for producing protein by using the same |
US6835390B1 (en) | 2000-11-17 | 2004-12-28 | Jon Vein | Method for producing tissue engineered meat for consumption |
DE102004017484B4 (en) | 2004-04-08 | 2006-07-06 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Process for the preparation of a biological material composition of animal origin |
US20060121006A1 (en) | 2004-09-10 | 2006-06-08 | Chancellor Michael B | Production of nutritional and therapeutic products from cultured animal cells |
ES2378822T3 (en) | 2004-09-17 | 2012-04-18 | Jon Vein | Tissue engineering meat for consumption and method for producing tissue engineering meat for consumption |
EP1956923A1 (en) * | 2005-11-02 | 2008-08-20 | Nestec S.A. | Isoflavone compositions for reducing accumulation of body fat in male mammals, and methods for their use |
DE102007029699B4 (en) | 2007-06-27 | 2010-12-02 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Isolated proliferating cells having stem cell characteristics from adult tissues of vertebrate vertebrates, stable cell cultures thereof, and methods for their production |
CN101624570B (en) | 2008-07-07 | 2011-04-13 | 刘志军 | Method for cultivating cultured ganoderma lucidum with Chinese medicaments and method for preparing cultured ganoderma lucidum health-care product |
WO2010068897A2 (en) | 2008-12-12 | 2010-06-17 | Kedar Challakere | Stem cell enhanced protein products and uses thereof |
US20110091604A1 (en) | 2009-10-21 | 2011-04-21 | Seth Adrian Miller | Synthetic meat |
WO2012034101A2 (en) | 2010-09-09 | 2012-03-15 | The Regents Of The University Of California | Expandable cell source of neuronal stem cell populations and methods for obtaining and using them |
BR112013031770A2 (en) * | 2011-06-10 | 2016-12-06 | Univ Georgia | induced pluripotency avian stem cell population, chimeric bird, reprogamation method of an avian embryonic cell or adult somatic cell, method of genetic manipulation of avian species, method of instilling disease resistance into an induced pluripotent avian stem cell, method of instilling disease resistance in a pluripotent avian stem cell population, method for producing a chimeric bird gamete, method of producing immunogenic material for a vaccine and vaccine |
CA2780087A1 (en) | 2011-06-14 | 2012-12-14 | Jacques P. Tremblay | Myogenic differentiation of stem cells and uses thereof |
WO2012176023A1 (en) | 2011-06-23 | 2012-12-27 | Indian Institute Of Technology Kanpur | Hydrogel scaffolds for tissue engineering |
BR112014000614A2 (en) | 2011-07-12 | 2017-07-11 | Maraxi Inc | consumable methods and compositions |
KR20140050064A (en) | 2011-07-26 | 2014-04-28 | 더 큐레이터스 오브 더 유니버시티 오브 미주리 | Engineered comestible meat |
CA2792081C (en) * | 2011-10-11 | 2020-10-27 | Bond University Ltd | Layered compositions comprising 3d nanofibre webbing for tissue repair |
US9862929B2 (en) * | 2011-11-18 | 2018-01-09 | Kyoto University | Method of inducing differentiation from pluripotent stem cells to skeletal muscle cells |
US9737875B2 (en) | 2012-03-16 | 2017-08-22 | Impossible Foods Inc. | Affinity reagents for protein purification |
US10039306B2 (en) | 2012-03-16 | 2018-08-07 | Impossible Foods Inc. | Methods and compositions for consumables |
CN104603293A (en) | 2012-03-28 | 2015-05-06 | 现代牧场有限公司 | Engineered leather and methods of manufacture thereof |
WO2014110540A1 (en) | 2013-01-11 | 2014-07-17 | Maraxi, Inc. | Non-dairy cheese replica comprising a coacervate |
PT2959005T (en) | 2013-02-22 | 2021-12-30 | Univ Leland Stanford Junior | Compounds, compositions, methods, and kits relating to telomere extension |
WO2015038988A1 (en) | 2013-09-13 | 2015-03-19 | Modern Meadow, Inc. | Edible and animal-product-free microcarriers for engineered meat |
WO2015066377A1 (en) | 2013-10-30 | 2015-05-07 | The Curators Of The University Of Missouri | Method for scalable skeletal muscle lineage specification and cultivation |
US20150296834A1 (en) | 2014-04-17 | 2015-10-22 | Savage River, Inc. dba Beyond Meat, Inc. | Plant based meat structured protein products |
US9526267B2 (en) | 2014-04-17 | 2016-12-27 | Savage River, Inc. | Nutrient-dense meat structured protein products |
MX2018000941A (en) | 2015-07-24 | 2019-08-29 | Synthetic Genomics Inc | A protein rich food ingredient from biomass and methods of production. |
KR20180134847A (en) | 2016-01-14 | 2018-12-19 | 멤피스 미츠 인코포레이티드 | Methods of increasing the replication capacity of somatic cells during in vitro culture |
EP3612623A4 (en) | 2017-05-06 | 2021-06-23 | Memphis Meats, Inc. | Compositions and methods for increasing the culture density of a cellular biomass within a cultivation infrastructure |
WO2019014652A1 (en) | 2017-07-13 | 2019-01-17 | Memphis Meats, Inc. | Compositions and methods for increasing the efficiency of cell cultures used for food production |
-
2014
- 2014-10-30 WO PCT/US2014/063250 patent/WO2015066377A1/en active Application Filing
- 2014-10-30 BR BR112016009803-0A patent/BR112016009803B1/en active IP Right Grant
- 2014-10-30 AU AU2014342180A patent/AU2014342180B2/en active Active
- 2014-10-30 CA CA2928726A patent/CA2928726A1/en active Pending
- 2014-10-30 US US15/033,207 patent/US20160251625A1/en not_active Abandoned
- 2014-10-30 EP EP14858383.4A patent/EP3071040B2/en active Active
- 2014-10-30 JP JP2016552246A patent/JP6728049B2/en active Active
- 2014-10-30 IL IL296889A patent/IL296889A/en unknown
- 2014-10-30 CN CN202010084479.7A patent/CN111154726A/en active Pending
- 2014-10-30 ES ES14858383T patent/ES2782380T5/en active Active
- 2014-10-30 CN CN201480061537.7A patent/CN105899079A/en not_active Withdrawn
-
2016
- 2016-04-20 US US15/134,252 patent/US10920196B2/en active Active
- 2016-04-24 IL IL245292A patent/IL245292B2/en unknown
-
2019
- 2019-04-02 AU AU2019202244A patent/AU2019202244B2/en active Active
-
2020
- 2020-01-17 JP JP2020005873A patent/JP2020089381A/en active Pending
-
2021
- 2021-02-12 US US17/175,324 patent/US20210171912A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0435617A1 (en) * | 1989-12-21 | 1991-07-03 | The University Of Georgia Research Foundation, Inc. | Bovine myogenic factor gene |
WO1993009236A1 (en) * | 1991-11-06 | 1993-05-13 | Baylor College Of Medicine | Myogenic vector systems |
US20110191871A1 (en) * | 2006-02-28 | 2011-08-04 | Trustees Of Boston University | Methods to identify factors associated with muscle growth and uses thereof |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10920196B2 (en) | 2013-10-30 | 2021-02-16 | The Curators Of The University Of Missouri | Method for scalable skeletal muscle lineage specification and cultivation |
US11318167B2 (en) | 2015-12-11 | 2022-05-03 | The Johns Hopkins University | Isolation of fusion-competent myoblasts and therapeutic applications thereof related to muscular dystrophy |
JP2019501657A (en) * | 2016-01-14 | 2019-01-24 | メンフィス ミーツ インコーポレイテッド | Method for expanding replication of somatic cells during in vitro culture process |
WO2017124100A1 (en) * | 2016-01-14 | 2017-07-20 | Memphis Meats, Inc. | Methods for extending the replicative capacity of somatic cells during an ex vivo cultivation process |
WO2018011805A2 (en) | 2016-07-11 | 2018-01-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Systems and methods for growing cells in vitro |
WO2018208628A1 (en) | 2017-05-06 | 2018-11-15 | Memphis Meats, Inc. | Compositions and methods for increasing the culture density of a cellular biomass within a cultivation infrastructure |
WO2018227016A1 (en) * | 2017-06-07 | 2018-12-13 | Wild Type, Inc. | Ex vivo meat production |
US20200140821A1 (en) * | 2017-06-07 | 2020-05-07 | Wild Type, Inc. | Ex vivo meat production |
IL271137B2 (en) * | 2017-06-07 | 2024-04-01 | Wild Type Inc | Ex vivo meat production |
IL271137B1 (en) * | 2017-06-07 | 2023-12-01 | Wild Type Inc | Ex vivo meat production |
US11708587B2 (en) | 2017-07-13 | 2023-07-25 | Upside Foods, Inc. | Compositions and methods for increasing the efficiency of cell cultures used for food production |
US11479792B2 (en) | 2017-07-13 | 2022-10-25 | Upside Foods, Inc. | Compositions and methods for increasing the efficiency of cell cultures used for food production |
WO2021102375A1 (en) | 2019-11-20 | 2021-05-27 | Memphis Meats, Inc. | Apparatuses and systems for preparing a meat product |
WO2021111263A1 (en) * | 2019-12-02 | 2021-06-10 | Avant Meats Company Limited | Methods for improving cell growth with species-specific or genus-specific proteins and the applications thereof |
WO2021158831A1 (en) | 2020-02-04 | 2021-08-12 | Upside Foods, Inc. | Characteristics of meat products |
WO2021248141A1 (en) | 2020-06-05 | 2021-12-09 | Upside Foods, Inc. | Nutrient media for the production of slaughter-free meat |
WO2021250407A1 (en) * | 2020-06-10 | 2021-12-16 | HigherSteaks Limited | Systems and methods for cell conversion |
GB2613467A (en) * | 2020-06-10 | 2023-06-07 | Highersteaks Ltd | Systems and methods for cell conversion |
WO2022039998A1 (en) | 2020-08-18 | 2022-02-24 | Upside Foods, Inc. | Systems, devices, and methods for sterilizing bioreactors and culture media |
WO2022140187A1 (en) * | 2020-12-21 | 2022-06-30 | Upside Foods, Inc. | Fluid conduit with radial expansion of fluid flow |
WO2022140185A1 (en) * | 2020-12-22 | 2022-06-30 | Upside Foods, Inc. | Systems and methods for cultivating tissue on porous substrates |
US11912967B2 (en) | 2020-12-22 | 2024-02-27 | Upside Foods, Inc. | Systems and methods for cultivating tissue on porous substrates |
WO2022156939A1 (en) * | 2021-01-22 | 2022-07-28 | HigherSteaks Limited | Products for cell conversion |
WO2022216742A1 (en) | 2021-04-07 | 2022-10-13 | Upside Foods, Inc. | Generation of cell-based products for consumption that comprise proteins derived from exotic, endangered, and extinct species |
WO2022232322A1 (en) | 2021-04-28 | 2022-11-03 | Upside Foods, Inc. | Generation of cell-based products for human consumption |
WO2022265632A1 (en) | 2021-06-16 | 2022-12-22 | Upside Foods, Inc. | Plant fat-based scaffolds for the growth of cell-based meats and methods of making such products |
WO2023281114A1 (en) | 2021-07-09 | 2023-01-12 | Suprême | Foodstuffs comprising cells differentiated from engineered oligopotent stem cells |
WO2023122688A1 (en) * | 2021-12-23 | 2023-06-29 | Upside Foods, Inc. | Scaling up myogenic tissue: late passage myogenicity |
GB202308833D0 (en) | 2022-06-14 | 2023-07-26 | Upside Foods Inc | Non-skeletal muscle-derived cells as a source of suspension capable myogenic cells for cultured foods |
EP4293109A1 (en) | 2022-06-14 | 2023-12-20 | Upside Foods, Inc. | Non-skeletal muscle-derived cells as a source of suspension capable myogenic cells for cultured foods |
EP4292440A1 (en) | 2022-06-14 | 2023-12-20 | Upside Foods, Inc. | Suspension based chicken product formulation |
WO2023242231A1 (en) | 2022-06-14 | 2023-12-21 | Upside Foods, Inc. | Non-skeletal muscle-derived cells as a source of suspension capable myogenic cells for cultured foods |
WO2023242230A1 (en) | 2022-06-14 | 2023-12-21 | Upside Foods, Inc. | Suspension based chicken product formulation |
GB2623396A (en) | 2022-06-14 | 2024-04-17 | Upside Foods Inc | Non-skeletal muscle-derived cells as a source of suspension capable myogenic cells for cultured foods |
Also Published As
Publication number | Publication date |
---|---|
EP3071040A1 (en) | 2016-09-28 |
CN105899079A (en) | 2016-08-24 |
JP6728049B2 (en) | 2020-07-22 |
CA2928726A1 (en) | 2015-05-07 |
JP2020089381A (en) | 2020-06-11 |
US20160227830A1 (en) | 2016-08-11 |
CN111154726A (en) | 2020-05-15 |
AU2014342180A1 (en) | 2016-05-19 |
EP3071040B1 (en) | 2020-01-01 |
EP3071040B2 (en) | 2022-12-28 |
BR112016009803B1 (en) | 2022-02-08 |
AU2019202244A1 (en) | 2019-04-18 |
BR112016009803A2 (en) | 2017-12-05 |
BR112016009803A8 (en) | 2018-01-30 |
AU2019202244B2 (en) | 2021-09-23 |
IL245292B (en) | 2022-10-01 |
IL245292B2 (en) | 2023-02-01 |
JP2016535601A (en) | 2016-11-17 |
ES2782380T5 (en) | 2023-05-08 |
EP3071040A4 (en) | 2017-06-21 |
AU2014342180B2 (en) | 2019-01-03 |
ES2782380T3 (en) | 2020-09-14 |
US20160251625A1 (en) | 2016-09-01 |
US20210171912A1 (en) | 2021-06-10 |
IL245292A0 (en) | 2016-06-30 |
US10920196B2 (en) | 2021-02-16 |
IL296889A (en) | 2022-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210171912A1 (en) | Method for scalable skeletal muscle lineage specification and cultivation | |
Xu et al. | A zebrafish embryo culture system defines factors that promote vertebrate myogenesis across species | |
EP2955223B1 (en) | Production methods for megakaryocytes and platelets | |
JP6905938B2 (en) | Return of prime-type pluripotent stem cells to naive-type pluripotent stem cells | |
JP6351018B2 (en) | Stem cell differentiation induction method using amino acid composition modified medium, and medium kit containing the medium | |
Kim et al. | Induction of pluripotent stem cell-like cells from chicken feather follicle cells | |
Zhang et al. | Generation of functional brown adipocytes from human pluripotent stem cells via progression through a paraxial mesoderm state | |
EP3421598B1 (en) | Method for promoting differentiation of pluripotent stem cells by reducing undifferentiated state thereof | |
US11697798B2 (en) | Enhanced differentiation and maturation of pluripotent stem cell-derived myogenic cells | |
CA3141813A1 (en) | Compositions and methods for cellular reprogramming | |
Han et al. | SCNT versus iPSCs: proteins and small molecules in reprogramming. | |
WO2017073763A1 (en) | Method for reducing differentiation resistance of pluripotent stem cells | |
JP7323966B1 (en) | Method for producing culture composition | |
US20240131080A1 (en) | Method for reprogramming human cells | |
Sandoval et al. | Tumor suppressors inhibit reprogramming of African spiny mouse (Acomys) fibroblasts to induced pluripotent stem cells | |
Zhang | Thermogenic Adipocytes Generated from Human Stem Cells Have Therapeutic Utilities | |
CA3221942A1 (en) | Foodstuffs comprising cells differentiated from engineered oligopotent stem cells | |
McMillan et al. | Towards' in vitro'produced germline stem cells in the bovine | |
WO2023067090A1 (en) | Ipsc induction and progeny derivation | |
WO2022264132A1 (en) | Method for reprogramming human cells | |
Page et al. | Methods for Inducing Pluripotency |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14858383 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 245292 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2928726 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2016552246 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15033207 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016009803 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2014342180 Country of ref document: AU Date of ref document: 20141030 Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2014858383 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014858383 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 112016009803 Country of ref document: BR Kind code of ref document: A2 Effective date: 20160429 |